Pharmacology & Medication Management Flashcards
7 cards from real Addiction Medicine Certification practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 7 Pharmacology & Medication Management flashcards as text
A patient on buprenorphine for OUD undergoes elective surgery. Which perioperative pain management strategy is most appropriate?
Answer: Continue buprenorphine and supplement with multimodal analgesia including higher-dose full opioid agonists if needed
Current evidence and guidelines support continuing buprenorphine perioperatively and using multimodal analgesia; discontinuation risks relapse and full opioid agonist requirements are simply higher due to receptor occupancy.
Which of the following is the mechanism by which gabapentin may be used as an adjunct in alcohol use disorder treatment?
Answer: It reduces glutamate release and modulates alpha-2-delta calcium channel subunits, reducing cravings and withdrawal symptoms
Gabapentin modulates voltage-gated calcium channels (alpha-2-delta subunit) and reduces glutamate activity, helping alleviate protracted alcohol withdrawal symptoms and cravings.
Patients taking methadone should be monitored for which electrolyte abnormality that can worsen QTc prolongation?
Answer: Hypomagnesemia and hypokalemia
Hypomagnesemia and hypokalemia both prolong cardiac repolarization and can potentiate methadone-induced QTc prolongation, increasing the risk of torsades de pointes.
In the MATRICS framework for opioid use disorder pharmacotherapy, which of the following is NOT an FDA-approved medication for OUD?
Answer: Clonidine
Clonidine is not FDA-approved for OUD treatment; it is used off-label to manage opioid withdrawal symptoms such as anxiety, agitation, and autonomic hyperactivity.
A patient with stimulant use disorder (cocaine) asks about medication options. Which statement best reflects the current evidence?
Answer: No medications are currently FDA-approved specifically for stimulant use disorder, though some are used off-label
As of the current evidence base, no medications are FDA-approved specifically for stimulant (cocaine or methamphetamine) use disorder, though various agents are investigated and used off-label.
When prescribing buprenorphine in the outpatient setting, the DATA 2000 waiver (now superseded by the Mainstreaming Addiction Treatment Act of 2023) primarily changed which aspect of prescribing?
Answer: It eliminated the separate waiver requirement, allowing any DEA-licensed prescriber to prescribe buprenorphine for OUD
The Mainstreaming Addiction Treatment (MAT) Act of 2023 eliminated the separate X-waiver requirement, allowing any DEA-registered practitioner to prescribe buprenorphine for OUD without additional certification.
Which of the following best describes the role of lofexidine (Lucemyra) in opioid use disorder management?
Answer: It is an alpha-2 adrenergic agonist FDA-approved to mitigate opioid withdrawal symptoms
Lofexidine is an alpha-2 adrenergic agonist FDA-approved in 2018 for mitigation of opioid withdrawal symptoms; it reduces noradrenergic hyperactivity during withdrawal but does not treat OUD itself.
How this page was made: written with AI tools and published by Nathan Beja, founder of Practice Test Geeks, who is responsible for its content. Exam facts are checked against the official sources listed below. Not reviewed by a subject-matter expert. Editorial policy
Sources & references
Exam facts on this page (fees, format, dates, passing scores) are checked against these official sources; the date is our last check. Editorial policy
- theabpm.org — Fees, late registration, registration, test dates, eligibility, retake policy, score release, exam format · verified Oct 2026
- pearsonvue.com — Test delivery · verified Oct 2026